Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Operating Expenses (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Other Operating Expenses for 7 consecutive years, with $592000.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 83.24% to $592000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, up 4.59% year-over-year, with the annual reading at $6.5 million for FY2025, 85.28% up from the prior year.
  • Other Operating Expenses hit $592000.0 in Q4 2025 for Seres Therapeutics, down from $736000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $3.6 million in Q1 2023 to a low of -$346000.0 in Q4 2022.
  • Historically, Other Operating Expenses has averaged $1.2 million across 5 years, with a median of $976000.0 in 2022.
  • Biggest five-year swings in Other Operating Expenses: crashed 157.19% in 2022 and later skyrocketed 877.12% in 2023.
  • Year by year, Other Operating Expenses stood at $605000.0 in 2021, then plummeted by 157.19% to -$346000.0 in 2022, then skyrocketed by 708.67% to $2.1 million in 2023, then surged by 67.71% to $3.5 million in 2024, then tumbled by 83.24% to $592000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for MCRB at $592000.0 in Q4 2025, $736000.0 in Q3 2025, and $185000.0 in Q2 2025.